About OralDNA
OralDNA is a Healthcare company based in Eden Prairie (United States) founded in 2009 by Ken Clarke, Brian Carr, Russell Nabors, and Tom Nabors, and was acquired by Access Genetics in November 2012. Saliva-based tests for periodontal disease and infections are developed. Its chief executive, as recorded, is Brian Carr. OralDNA offers products and services including MyPerioPath, MyPerioID, and OraRisk HPV. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Access Genetics LLC. Its competitors include Inflammatix, Karius and Day Zero Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2009 in Eden Prairie, United States, and operates in the healthcare diagnostics sector. Saliva-based molecular tests are provided for early detection of periodontal disease, HPV strains linked to oral cancers, and other infections including HSV, Candida, Chlamydia, and Neisseria gonorrhea. Genetic markers for inflammatory responses are also assessed, along with pharmacogenetic tests to predict drug responses.
- Headquarters Eden Prairie, United States
- Founders Ken Clarke, Brian Carr, Russell Nabors, Tom Nabors
- Stage Acquired
- SectorsHealthcare
- Website category Health · Dentist and Dental Services
- Website oraldna.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Access Genetics (Nov 2012)
- Legal Name Access Genetics Llc
- Investors
- Acquired byAccess Genetics
(Nov 2012)
Products & Services of OralDNA
OralDNA offers a comprehensive portfolio of products and services, including MyPerioPath, MyPerioID, and OraRisk HPV.
Early detection tool for periodontal disease using saliva.
Targeted treatment aid for personalized oral care.
Assesses risk for HPV-related oral cancers.
Apps and channels of OralDNA
its YouTube channel OralDNA Labs has 120 subscribers and 17 videos.
Videos from OralDNA
The most watched videos on OralDNA's YouTube channel, OralDNA Labs (120 subscribers). Click a video to play it here.
More on OralDNA Labs.
Investors in OralDNA
OralDNA has secured backing from 1 investor. Prominent investors backing the company include Access Genetics & OralDNA Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Personalized diagnostics are provided through advanced DNA testing. | access-genetics.com | Eden Prairie, United States |
Investor details for OralDNA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OralDNA
4 people are tracked at OralDNA (4 in leadership).
| Name | Role | Group |
|---|---|---|
Ken Clarke | Co-Founder | Leadership |
Brian Carr | Co-Founder & CEO | Leadership |
Russell Nabors | Co-Founder | Leadership |
Tom Nabors | Co-Founder | Leadership |
Complete people profiles for OralDNA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OralDNA
2 dated milestones of OralDNA across 3 years, from founding to its latest funding, stage changes and deals.
- Founded OralDNA is founded.
- Exit Acquired by Access Genetics.
Competitors of OralDNA
OralDNA has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Karius and Day Zero Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. |
Detailed competitors of OralDNA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OralDNA
The website of OralDNA (oraldna.com) receives about 7.1K visits a month and ranks #3,709,579 among all websites worldwide, #4,343 in Dentist and Dental Services.
- Monthly visits7.1K
▲ 34.7% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,709,579
among all websites
- Category rank#4,343
Health · Dentist and Dental Services
- Bounce rate47%
- Pages per visit1.6
- Average visit27 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with OralDNA. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| perio.org | 100% | #354,023 | View details | ||
| ada.org | 87% | 987.4K | #51,155 | View details | |
snaponsmile.com | snaponsmile.com | 87% | #2,808,895 | – | |
| dexis.com | 87% | 134.4K | #390,462 | View details | |
charnyhealing.com | charnyhealing.com | 76% | #1,513,119 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for OralDNA
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as OralDNA (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oraldna
Complete news archive for OralDNA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OralDNA
OralDNA was founded in 2009.
OralDNA is headquartered in Eden Prairie, United States. It is registered at Eden Prairie, Minnesota, United States.
Brian Carr is the CEO of OralDNA, as recorded in our data. They have also founded this company.
The company was founded in 2009 in Eden Prairie, United States, and operates in the healthcare diagnostics sector. Saliva-based molecular tests are provided for early detection of periodontal disease, HPV strains linked to oral cancers, and other infections including HSV, Candida, Chlamydia, and Neisseria gonorrhea. Genetic markers for inflammatory responses are also assessed, along with pharmacogenetic tests to predict drug responses.
OralDNA's top competitors include Inflammatix, Day Zero Diagnostics and Karius.
OralDNA offers MyPerioPath, MyPerioID, and OraRisk HPV.
OralDNA has 1 investor. Key investors include Access Genetics & OralDNA Labs.
OralDNA operates through Access Genetics Llc.
Yes. OralDNA was acquired by Access Genetics in November 2012.